MOLECULAR INFORMATION
Molecular information
- Type
- HDM-2 binding domain of p53 fused to membrane-residency peptide · cancer-selective lytic
PNC27 is a research-stage anticancer peptide with no clinical authorisation, sold grey-market with claims that exceed the evidence.
Claims vs evidence
- Selective cancer-cell lysis via HDM-2 binding — preclinical mechanism
- Tumour regression in humans — no clinical trial data
- Safe to self-administer — unsupported
Why we grade it D
Real preclinical mechanism, zero clinical translation. Self-administration for cancer is editorially indefensible — patients should access evidence-based oncology, not grey-market peptides.
Frequently asked questions
- What is PNC27?
- A chimeric peptide combining the HDM-2 binding domain of p53 with a membrane-residency sequence. Designed to selectively bind HDM-2 expressed on cancer cell membranes and induce lytic cell death.
- Is PNC27 a cancer treatment?
- It is an experimental compound studied in cancer-research contexts since the early 2000s. No clinical trial has progressed to authorisation, and there is no validated role in oncology practice.
- Is it safe to use?
- No — sold grey-market with extrapolated cancer-treatment claims that exceed the published data. People with cancer should consult oncologists; using PNC27 outside formal trials carries unknown safety and may delay evidence-based care.